Lookup NU author(s): Dr Emma Kampouraki,
Professor Farhad Kamali
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.Introduction: The inclusion of pharmacogenetics alongside clinical information in anticoagulant therapy offers the opportunity for a tailored approach to treatment according to individual patient characteristics. Areas covered: Literature was searched using PubMed database, focusing on pharmacogenetics of oral anticoagulants. Original research articles and review articles in English language were included in the literature reviewed. This article includes all information available for the genetic cause of inter-individual variability in anticoagulation response to oral anticoagulant drugs. The pharmacogenetics of VKAs and NOACs are described in detail. Expert opinion: There have been numerous studies focusing on the pharmacogenetics of VKAs, particularly warfarin. Current evidence suggests that known genetic and clinical factors explain a large proportion of the inter-individual variability in response to warfarin. Pharmacogenetic-based algorithms have been validated to determine their clinical utility with equivocal results. To date, only a limited number of mostly small studies on the pharmacogenetics of NOACs exists. The latter have highlighted genetic polymorphisms in specific genes that may affect clinical outcomes. Further evaluations of these polymorphisms are needed before firm conclusions can be drawn about the significance of pharmacogenetics on NOAC therapy.
Author(s): Kampouraki E, Kamali F
Publication type: Article
Publication status: Published
Journal: Expert Opinion on Drug Metabolism and Toxicology
Online publication date: 23/05/2019
Acceptance date: 22/05/2019
ISSN (print): 1742-5255
ISSN (electronic): 1744-7607
Publisher: Taylor and Francis Ltd
PubMed id: 31120800
Altmetrics provided by Altmetric